

Research Article

Quercetin Prevents Diastolic Dysfunction Induced by a High-Cholesterol Diet: Role of Oxidative Stress and Bioenergetics in Hyperglycemic Rats

Rodrigo L. Castillo ¹, Emilio A. Herrera ^{1,2}, Alejandro Gonzalez-Candia ¹,
Marjorie Reyes-Farias,³ Nicole de la Jara,³ Juan Pedro Peña,^{4,5,6}
and Catalina Carrasco-Pozo ^{3,7}

¹Pathophysiology Program, ICBM, Faculty of Medicine, University of Chile, Av. Salvador 486, Providencia, 7500922 Santiago, Chile

²International Center for Andean Studies, Universidad de Chile, Putre, Chile

³Department of Nutrition, Faculty of Medicine, University of Chile, Santiago, Chile

⁴Universidad de Viña del Mar, Región de Valparaíso, Chile

⁵Centro de Simulación Clínica, Universidad Iberoamericana, Santiago, Chile

⁶Servicios Médicos Veterinarios de Especialidad-VETCO, Santiago, Chile

⁷Discovery Biology, Griffith Institute for Drug Discovery, Griffith University, Nathan, QLD 4111, Australia

Correspondence should be addressed to Catalina Carrasco-Pozo; catapaco@gmail.com

Received 6 August 2017; Accepted 23 October 2017; Published 11 January 2018

Academic Editor: Vladimir Jakovljevic

Copyright © 2018 Rodrigo L. Castillo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Alterations in cardiac energy metabolism play a key role in the pathogenesis of diabetic cardiomyopathy. Hypercholesterolemia associated with bioenergetic impairment and oxidative stress has not been well characterized in the cardiac function under glycemic control deficiency conditions. This work aimed to determine the cardioprotective effects of *quercetin* (QUE) against the damage induced by a high-cholesterol (HC) diet in hyperglycemic rats, addressing intracellular antioxidant mechanisms and bioenergetics. Quercetin reduced HC-induced alterations in the lipid profile and glycemia in rats. In addition, QUE attenuated cardiac diastolic dysfunction (increased E:A ratio), prevented cardiac cholesterol accumulation, and reduced the increase in HC-induced myocyte density. Moreover, QUE reduced HC-induced oxidative stress by preventing the decrease in GSH/GSSG ratio, Nrf2 nuclear translocation, HO-1 expression, and antioxidant enzymatic activity. Quercetin also counteracted HC-induced bioenergetic impairment, preventing a reduction in ATP levels and alterations in PGC-1 α , UCP2, and PPAR γ expression. In conclusion, the mechanisms that support the cardioprotective effect of QUE in rats with HC might be mediated by the upregulation of antioxidant mechanisms and improved bioenergetics on the heart. Targeting bioenergetics with QUE can be used as a pharmacological approach to modulate structural and functional changes of the heart under hypercholesterolemic and hyperglycemic conditions.

1. Introduction

Hypercholesterolemia is a major risk factor for developing cardiovascular diseases. It further induces oxidative stress, resulting in increased lipid peroxidation in multiple organs [1]. Previous studies have also indicated that hypercholesterolemia is causally linked to a significant increase in reactive oxygen species (ROS) with concomitant lower antioxidant

capacity in cardiac tissue [2, 3]. In addition, high cholesterol (HC) levels may activate endothelial cells and lead to increased production of ROS [4, 5]. This mechanism induces vascular function impairment, cell proliferation, cell death, and cardiac remodeling [6, 7]. Indeed, a HC diet leads to oxidative stress, spontaneous arterial vasoconstriction, and systemic hypertension [8] as well as Western diet-induced biventricular cardiomyocyte hypertrophy, increased

stiffness, and impaired relaxation in rats [9]. However, the effects of a high-cholesterol diet on bioenergetics and oxidative stress on the impairment of the cardiac function are only partially known and no treatment has shown compelling effectiveness.

Over the last decade, a growing interest has been focused on dietary flavonoids with antioxidant properties such as radical scavenging, metal chelating, and antioxidant enzyme modulation [10]. More recently, it has been shown that flavonoids can also improve intracellular bioenergetics [11, 12]. These compounds could exert cardioprotective effects due to their ability to attenuate oxidative stress, among others. Interestingly, other key mechanisms to preserve cardiovascular function, such as energy supply and turnover, have not been characterized in response to these compounds. Quercetin (QUE) is the most abundant and common flavonoid in the human diet, emphasizing its high antioxidant activity [13]. Quercetin has been shown to protect against mitochondrial dysfunction induced by a HC diet in the pancreas, preserving bioenergetics of pancreatic β -cells [12]. The cardioprotective effects of QUE supplementation have been studied in paradigms of myocardial and vascular injury mediated by oxidative stress [14, 15]; however, the molecular mechanisms involved in the functional protective response have not been fully characterized.

We hypothesized that QUE has cardiac protective effects exerted by the upregulation of intracellular antioxidant mechanisms and by the improvement in bioenergetics. Therefore, the aim of this study was to determine the cardiac function, antioxidant capacity, and bioenergetic molecular mechanisms supporting the cardiac effects of QUE supplementation in rats fed with a high-cholesterol diet.

2. Materials and Methods

2.1. Animals and Diets. The study protocol was approved by the Animal Ethics Committee of the Faculty of Medicine of the University of Chile (CBA#0586 FMUCH), and all procedures were performed in compliance with the Guidelines for Care and Use of Laboratory Animals.

Forty male Wistar rats (90–110 g, 5–6 weeks old) from the Faculty of Medicine were housed in a 12 h light/dark schedule at room temperature with water ad libitum and were randomly distributed into 5 groups. These groups consisted in (1) standard diet fed (C, $n = 8$; AIN-76A/Clinton-Cybulsky Cholesterol Series #1–107); (2) standard diet supplemented with quercetin (CQ, $n = 8$, 0.5% w/w); (3) high-cholesterol diet (HC, $n = 8$, 1.25% cholesterol w/w , AIN-76A/Clinton-Cybulsky Cholesterol Series #3–107); and (4) HC diet supplemented with either quercetin (HCQ, $n = 8$, 0.5% w/w) or (5) ezetimibe (HCE, $n = 8$, 0.001% w/w) for 4 weeks. Ezetimibe blocks Niemann-Pick C1 Like 1 (NPC1L1) protein in the small intestine, a transporter that mediates cholesterol absorption [16]. The doses of quercetin and ezetimibe used in this study are based in a previous study developed by our group [12]. Quercetin was obtained from Sigma-Aldrich (catalogue number 337951, Germany), and ezetimibe was from MSD Chile (Ezetrol®, Chile).

2.2. Echocardiographic Analysis. After 4 weeks of treatment, ultrasound and Doppler examinations were performed to the animals under ketamine:xylazine anaesthesia (80 mg/kg:10 mg/kg, i.p.) using a Sonosite 180 plus echocardiograph equipped with an electronic 10 MHz linear-array transducer. During the echocardiographic examination, we determined the wall thickness (AWT), left and right ventricular end-systolic cavity (L-R, VESC), and left and right end diastolic cavity (L-R, VEDC). Ejection fraction (EF, %) and fractional shortening (FS, %) were calculated according to the formulas $EF = [(LVEDV - LVESV)/LVEDV] \times 100(\%)$ and $FS = [(LVEDC - LVESC)/LVEDC] \times 100(\%)$ [17]. Further, aortic maximal and mean velocity (V_{max} and V_{mean}) and mean peak gradient (mPG) were assessed by power Doppler.

Transmitral inflow Doppler obtained in an apical 4-chamber view or LV long-axis view was used for the evaluation of LV diastolic function [18]. The Doppler indexes include the ratio of peak velocity of early to late filling of mitral inflow (E/A) and the isovolumetric relaxation time (IVRT).

2.3. Sample Collection and Determinations

2.3.1. Basal Blood Glucose. By the end of the 4 weeks of treatment, tail blood glucose levels were determined during the morning in 12 h-fasted animals using an Accu-check glucometer (Roche, Mannheim, Germany).

Twenty-four hours after, we collected central venous blood and heart from animals euthanised under ketamine:xylazine anaesthesia (100 mg/kg:10 mg/kg, i.p.) and posterior exsanguination.

2.3.2. Plasma Cholesterol. Cholesterol was determined using a colorimetric enzymatic kit (Colestat, Wiener Lab, Argentina). Further, lipid profile (LDL, VLDL, and HDL) was performed by Laboratorio Clinico de Medicina Nuclear (Santiago, Chile).

2.3.3. Heart Collection. The hearts were removed and weighed. Half of the cardiac tissue was stored in 4% paraformaldehyde and embedded in paraffin for histological analyses, and the other half was frozen and stored at -80°C for biochemical and molecular biology analyses.

2.4. Cardiac Histology. Heart tissue was washed in PBS immersed-fixed with 4% PFA for 24 h at 4°C . Fixed samples were embedded in paraffin and cut in $4\ \mu\text{m}$ slides. Hematoxylin-Eosin and Van Gieson staining were performed for myocardial density in images captured at 40x and 400x with a digital camera coupled to a microscope (Olympus BX-41). The analysis of the microphotographs was performed with the software Image Pro-Plus 6.2 (Media Cybernetics Inc., Rockville, MD, USA). Briefly, the complete cardiac analysis consisted in the determination of the luminal area of the left and right ventricles and the thickness of the septum and both ventricular free walls. In addition, for each ventricle wall and septum, we calculated the myocardial cellular density as the number of nuclei/area.

2.5. Oxidative Stress Markers. The intracellular redox status in cardiac tissue was assessed by a fluorometric method in order to measure the oxidized glutathione (GSSG) and reduced glutathione (GSH) and to determine the GSH/GSSG ratio [19]. The inter- and intra-assay CVs for GSH and GSSG were 3.1% and 4.2%; and 2.7% and 3.5%, respectively.

Lipid peroxidation was assessed by the thiobarbituric acid reaction at pH 3.5, followed by solvent extraction with a mixture of n-butanol/pyridine (15:1, v/v) [20]. Tetramethoxypropane was used as the external standard, and the levels of lipid peroxides were detected spectrophotometrically at 532 nm and were expressed as mmol TBARS/mg protein. The interassay and intra-assay CVs for TBARS were 10.5% and 4.8%, respectively.

Plasma 8-isoprostane concentration (pmol/mL) was determined using an ELISA kit (Cayman, Ann Arbor, MI, USA) [Milne, 2005]. The inter- and intra-assay CVs were 9.5% and 10.7%, respectively.

2.6. Antioxidant Defenses. Heart lysates were homogenized in 0.25 M sucrose for the determination of Cu-Zn superoxide dismutase (SOD) activity or in 1.15% KCl 10 mM Tris/HCl buffer (pH 7.4) for catalase (CAT) and glutathione peroxidase (GSH-Px) activities. The Cu-Zn SOD assay is based on the SOD-mediated increase in the rate of autooxidation of catechols in an aqueous alkaline solution in order to yield a chromophore with a maximum absorbance at 525 nm [21]. One Cu-Zn SOD unit is defined as the activity that doubles the autooxidation background, and the results are expressed as units/mg of protein. CAT activity was assayed by the breakdown kinetic of peroxide of hydrogen (H_2O_2) at 240 nm and was expressed as the first-order reaction rate constant (k)/mg of protein [22]. Soluble GSH-Px activity was measured spectrophotometrically in a cytosolic fraction by the reduction of glutathione disulfide coupled to NADPH oxidation by glutathione reductase [23]. One GSH-Px unit is defined as the activity that oxidizes $1 \mu\text{mol}$ of NADPH/min and is expressed as units/mg of protein.

To evaluate Nrf2 translocation, nuclei were extracted from cardiac tissue as previously described [24] and an Nrf2 transcription factor assay kit was used to assess Nrf2 DNA binding activities (Cayman, MI, USA).

2.7. Transcript Measurements. The mRNA levels of *HO-1*, peroxisome proliferator-activated receptor gamma coactivator 1-alpha (*PGC-1 α*), and uncoupling protein 2 (*UCP2*) were evaluated by qPCR [25]. The expression of each gene is relative to the cycle thresholds of two housekeeping genes, *Actb* and *GADPH*. Primer sequences are provided in Supplementary Table 1.

2.8. Statistical Analysis. Data were analysed by one-way or two-way ANOVA, followed by Tukey's multiple comparison test using GraphPad Prism 6 (La Jolla, CA, USA). Unless indicated otherwise, the biochemical and molecular biology experiments were performed in triplicate or quadruplicate. Values are expressed as mean \pm SEM.

3. Results

3.1. Quercetin Ameliorates Cholesterol-Induced Alterations in the Lipid Profile. Four weeks of high-cholesterol (HC) feeding in rats resulted in a 74% and 36% increase in total plasma cholesterol and glucose levels, respectively (Figures 1(a) and 1(b)). HC diet increased the triglycerides, LDL, and VLDL plasma levels by 70%, 114%, and 100%, respectively, and reduced the HDL plasma levels by 63% (Figures 1(c), 1(d), 1(e), and 1(f)). Quercetin fully prevented the HC-induced increase in the plasma levels of total cholesterol, glucose, and triglycerides (Figures 1(a), 1(b), and 1(c)). In addition, QUE only prevented the increase in LDL by 57% and VLDL by 59% (Figures 1(d) and 1(e)). Furthermore, QUE prevented the decrease in HDL by 25% (Figure 1(f)). Quercetin had no effect on cholesterol levels and lipid profile when supplemented the control diet. Conversely, ezetimibe totally prevented the increase in the plasma levels of total cholesterol (Supplementary Figure 1A) and glucose (data not shown) induced by HC diet.

3.2. Quercetin Prevented Cholesterol-Induced Cardiac Dysfunction. The HC diet increased the A wave by 55% and decreased the E:A ratio by 50% (Figures 2(a) and 2(b)). Quercetin totally prevented the HC-induced alterations on cardiac diastolic function (Figures 2(a) and 2(b)). In contrast, cardiac systolic (EF, % and SF, %) and structural (left and right) ventricular parameters were similar between groups (Table 1).

3.3. Quercetin Prevented Cholesterol-Induced Composition and Morphological Alterations in the Heart. The HC diet increased the accumulation of cholesterol in cardiac tissue by 41% and the weight of the heart by 15% (Figures 3(a) and 3(b)). However, quercetin prevented the HC-induced increase in cardiac cholesterol and weight of the heart (Figures 3(a) and 3(b)). Quercetin had no effect on the accumulation of cholesterol in cardiac tissue and on the weight of the heart when supplemented the control diet. Interestingly, ezetimibe also prevented the increase in cardiac cholesterol and weight of the heart induced by HC diet (Supplementary Figures 1B and 1C).

The right ventricle wall and septum thickness were similar between the four experimental groups. However, the left ventricle wall thickness was increased in HC, an effect that was reverted by quercetin treatment (Figures 4(a), 4(b), and 4(c)). In addition, the right ventricle luminal area was similar between groups, although there was a clear tendency to decrease in HC group that was not seen in the HCQ animals (Figure 4(d)). By contrast, the left ventricle luminal area was significantly decreased in HC animals, and this effect was fully reverted by quercetin (Figure 4(e)).

Myocyte density tends to increase in the right ventricular free wall and septum in HC group relative to controls. Further, QUE significantly decreases myocyte density relative to HC (Figures 5(a) and 5(b)). In contrast, in the left ventricle free wall, there were no differences between groups (Figure 5(c)).

3.4. Quercetin Prevented Cholesterol-Induced Decrease in Antioxidant Defenses. The HC diet decreased the GSH/GSSG ratio by 43% (Figure 6(a)), Nrf2 translocation to the nucleus




FIGURE 1: Quercetin protects against the alteration on plasma cholesterol and glycemia levels and lipid profile induced by high-cholesterol diet. Plasma levels of (a) total cholesterol, (b) glucose, (c) triglycerides, (d) LDL, (e) VLDL, and (f) HDL from 12 h fasted rats, fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin (CQ), high-cholesterol diet (HC), or high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

by 57% (Figure 6(b)), and HO-1 expression by 45% (Figures 6(b) and 6(c)). In addition, the HC decreased the activity of SOD by 43% (Figure 6(d)) and tended to decrease the activity of catalase (Figure 6(e)) and GSH peroxidase (Figure 6(f)). Quercetin ameliorated the decrease on HC-induced GSH/GSSG ratio by 47% (Figure 6(a)). Further, QUE increased the Nrf2 translocation to the nucleus by 30%, the HO-1 expression by 55% in control diet-fed rats (Figures 6(b) and 6(c)), and by 178% and 139%, respectively, in HC diet-fed rats (Figures 6(b) and 6(c)). Quercetin enhanced the activity of SOD (Figure 6(d)), catalase (Figure 6(e)), and GSH peroxidase (Figure 6(f)) by 61%,

240%, and 81% in control diet-fed rats, respectively (Figures 6(e) and 6(f)). When supplemented with HC diet, QUE enhanced the activity of SOD (Figure 6(d)), catalase (Figure 6(e)), and GSH peroxidase (Figure 6(f)) by 75%, 163%, and 77%, respectively (Figures 6(d), 6(e), and 6(f)). Conversely, ezetimibe prevented the decrease on GSH/GSSG ratio induced by HC diet (Supplementary Figure 2A).

3.5. Quercetin Reduced Cholesterol-Induced Oxidative Stress.

The HC diet increased the levels of 8-isoprostanes in the heart by 154% when compared to control group (Figure 7(a)). Further, QUE diminished 8-isoprostanes by




FIGURE 2: Quercetin protects against cardiac diastolic dysfunction induced by high-cholesterol diet. Ultrasound and Doppler imaging showing (a) A wave (atrial filling velocity) expressed as cm/seg and (b) E:A, expressed as the ratio of peak velocity of early to late filling of mitral inflow, in rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin diet (CQ), high-cholesterol diet (HC), and high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$, ** $p < 0.01$, and *** $p < 0.001$.

TABLE 1: Cardiac structural and functional parameters determined by *in vivo* echocardiography.

	C	CQ	HC	HCQ
Cardiac parameters				
Ejection fraction (%)	75.2 \pm 7.1	72.5 \pm 6.3	69.1 \pm 6.7	72.7 \pm 7.3
Fractional shortening (%)	42.3 \pm 3.5	45.7 \pm 5.1	40.8 \pm 2.3	41.5 \pm 4.8
Heart rate, bpm	215 \pm 7.1	221 \pm 19	231 \pm 23	218 \pm 17
AWT, mm	1.6 \pm 0.3	1.9 \pm 0.4	2.3 \pm 0.4	2.1 \pm 0.4
LVEDC, mm	5.2 \pm 1.7	5.4 \pm 1.5	4.9 \pm 1.1	4.8 \pm 0.5
LVESC, mm	2.3 \pm 0.8	2.1 \pm 0.9	2.4 \pm 0.6	2.2 \pm 0.7
RVEDC, mm	1.9 \pm 0.5	2.1 \pm 0.7	2.2 \pm 0.6	1.8 \pm 0.4
RVESC, mm	2.7 \pm 0.6	2.4 \pm 0.5	3.0 \pm 0.8	2.9 \pm 0.4
Aortic				
Vmax, m/s	2.1 \pm 0.9	1.8 \pm 0.7	1.7 \pm 0.5	2.0 \pm 0.8
Vmean, m/s	1.1 \pm 0.4	0.9 \pm 0.5	0.9 \pm 0.3	1.2 \pm 0.4
Peak G max, mmHg	21.4 \pm 6.2	18.3 \pm 5.2	16.8 \pm 4.1	19.5 \pm 4.2
Peal G mean, mmHg	5.5 \pm 1.7	4.3 \pm 1.4	4.1 \pm 0.9	5.2 \pm 0.4
IVRT, ms	22.6 \pm 1.5	25.1 \pm 2.7	24.9 \pm 3.9	26.7 \pm 2.9

Values are mean \pm SEM. AWT: aortic wall thickness; LVEDC: left ventricular end-diastolic cavity; LVESC: left ventricular end-systolic cavity; RVEDC: right ventricular end-diastolic cavity; RVESC: right ventricular end-systolic cavity; Vmax: maximal velocity; G: gradient; IVRT: isovolumetric relaxation time.

74% in control diet-fed rats and by 47% in HC diet-fed rats (Figure 7(a)). Although HC diet did not increase lipid peroxidation compared to control diet (Figure 7(b)), QUE reduced the lipid peroxidation in HC diet-fed rats by 43% (Figure 7(b)) and ezetimibe decrease it by 39% (Supplementary Figure 2B).

3.6. *Quercetin Prevented Cholesterol-Induced Alteration in Bioenergetics.* The HC diet decreased the cardiac levels of ATP by 30% (Figure 8(a)) and the expression of *PGC-1 α* by 35% (Figure 8(b)) and increased the expression of *UCP2* by 64% and *PPAR γ* by 33% (Figures 8(c) and 8(d)), relative to control diet. The supplementation with QUE prevented the decrease in ATP levels and *PGC-1 α* expression (Figures 8(a) and 8(b)) and the increase in *UCP2* and *PPAR γ* expression in the heart from HC diet-fed rats (Figures 8(c) and 8(d)). In contrast, QUE had no effect when supplemented to control diet. Conversely, ezetimibe prevented the decrease on ATP levels and *PGC-1 α* expression and the increase on the expression of *UCP2* and *PPAR γ* induced by HC diet (Supplementary Figures 3A–3D).

4. Discussion

In this study, we demonstrated that a HC diet induces oxidative stress, bioenergetic impairment, and cardiac dysfunction associated with structural alterations. Furthermore, we showed that a treatment with QUE was able to prevent most of the metabolic and cardiac alterations.

Considering that QUE prevents impairments in plasma glucose regulation in this HC diet model [12], we find it particularly interesting to elucidate cardiovascular dysfunction mechanisms under hyperglycemia and hypercholesterolemia conditions induced by a HC diet. Cardiovascular disease is the major cause of morbidity and mortality in subjects suffering from diabetes mellitus where coronary artery disease is the leading cause of cardiac complications [26]. Although the protective effect of QUE against cardiac dysfunction induced by high cholesterol has been reported [27–29], these effects have not been studied under hyperglycemic conditions. Still, neither the molecular nor the metabolic mechanisms have been addressed. The novelty of




FIGURE 3: Quercetin protects against composition and morphological alterations induced by high-cholesterol diet. (a) The content of cholesterol and (b) weight of the heart were assessed in rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin (CQ), high-cholesterol diet (HC), or high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$.

the present study lies in the clarification of the molecular mechanisms related to redox homeostasis and bioenergetics that cause morphological and functional impairments induced by cholesterol and the cardiac protection given by QUE.

4.1. Cholesterol Causes Cardiovascular Dysfunction. The detrimental effects on the cardiovascular system induced by a HC diet can be attributed to the increased cholesterol levels in plasma and by the alteration of the lipid profile: increased triglyceride, LDL, and VLDL levels and decreased HDL levels. It is noteworthy that the HC diet induced cholesterol accumulation in the heart, suggesting that the deleterious effects on cardiac function are beyond its known atherogenic effect [30]. However, there were no significant differences in the variables of systolic function or in the dynamic measurements of either ventricle in the HC group. Therefore, it is likely that these data support some initial degree of altered ventricular relaxation, which may be due to initial states of systemic metabolic and inflammatory instability, such as hypercholesterolemia [31, 32].

Oxidative stress and biogenetic impairment were totally prevented when the increase in total cholesterol plasma levels, and therefore the amount of cholesterol in the heart, caused by the HC diet was reversed by supplementation with ezetimibe, a drug used to treat hypercholesterolemia by blocking NPC1L1-dependent cholesterol transport [16]. Quercetin prevented the increase in total cholesterol in plasma induced by HC, but it only partially prevented the alterations in lipid profile levels, as similarly reported in hypercholesterolemic Apo E^{-/-} mice [27]. Thus, the partial effect of QUE on preventing the HC diet-induced increase in LDL and VLDL levels supports the idea that the protective effect of QUE on cardiovascular function is beyond its effect on controlling total cholesterol levels.

4.2. Quercetin Protects against Oxidative Stress Induced by Cholesterol. Oxidative stress has a major role in the development of diabetic cardiomyopathy [33]. Therefore, we studied the prooxidant effects associated with the direct incorporation of cholesterol into the myocardium and cardiac dysfunction under hyperglycemia [12]. We found a prooxidant state in cardiac tissue, characterized by a decrease in antioxidant defenses and increased lipid peroxidation in HC diet-fed rats compared with control rats. Accumulation of cholesterol in the pancreas, leading to elevated oxidative stress, induced β -cell dysfunction with an impaired glucose-stimulated insulin secretion [12, 34]. Here, we consistently found increased cholesterol levels in cardiac tissue associated with oxidative stress and diastolic dysfunction in HC diet-fed rats.

Diastolic dysfunction, a recognized feature of diabetic cardiomyopathy [35] and alteration of ventricular relaxation, is associated with an increased ROS production from myocardium and endothelial sources [36]. Increased levels of cardiac ROS may explain some of the changes in Ca²⁺ handling proteins and the increased Ca²⁺ sensitivity of myofilaments that prompt the development of diastolic dysfunction and some types of arrhythmias [37]. Increased mitochondrial ROS have been observed in animal models of pressure overload and ventricular dysfunction [38] and in prediabetic animals with mild diastolic dysfunction [39]. Progression of diastolic dysfunction is associated with mitochondrial oxidative stress in a diet-induced diabetes model [40]. All of the above may induce systemic hypertension and cardiac remodeling. Although in our study we did not measure *in vivo* systemic arterial pressure, our finding suggests that the HC animals might be hypertensive and that QUE reverts this cardiovascular phenotype. In fact, the left ventricle wall of the HC animals was thicker and with a reduced lumen, a classical phenotype of cardiac remodeling due to an increased afterload, and these effects were




FIGURE 4: Quercetin protects against cardiac wall remodeling induced by high-cholesterol diet. (a) Right ventricle, (b) septum, and (c) left ventricle thicknesses; (d) right ventricle and (e) left ventricle luminal areas. (f) shows representative pictures of each group (millimetric bar: 2 mm). Heart dimensions were assessed in rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin (CQ), high-cholesterol diet (HC), or high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$ and ** $p < 0.01$.

prevented by QUE. Therefore, the use of antioxidants that attenuates mitochondrial injury may improve myocardial response to hemodynamic overload and optimize relaxation, decreasing left ventricular diastolic dysfunction. Interestingly, the mitochondria-targeted antioxidant mitoTEMPO prevented diastolic dysfunction in diabetic mice [41]. We found consistently that QUE, a polyphenolic antioxidant that accumulates in mitochondria [42, 43], protected against HC diet-induced diastolic dysfunction.

The role of Nrf2 has been widely described as a transcription factor related with cardioprotection [44]. The major aspects of Nrf2 are dependent on Nrf2-induced genes and their proteins including heme oxygenase-1

(HO-1). HO-1 by-products, such as carbon monoxide biliverdin and bilirubin, exert beneficial effects through the protection against oxidative damage, vascular inflammation, and cell death [45]. Even more, several studies have shown the cardiovascular benefits of HO-1 as reviewed elsewhere [46].

Quercetin has been shown to suppress LPS-induced oxidant production and adhesion molecule expression, crucial in initiation and progression of atherosclerosis, through the induction of Nrf2 activation and antioxidant enzyme expression in human aortic endothelial cells [47]. In the heart, QUE attenuated changes in cardiac function induced by high-carbohydrate/high-fat diet and prevented the decrease of Nrf2




FIGURE 5: Quercetin protects against increased myocyte density induced by high-cholesterol diet. (a) Right ventricle, (b) septum, and (c) left ventricle myocyte densities, assessed in rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin (CQ), high-cholesterol diet (HC), or high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$.

and HO-1 expressions [48]. Here, we report for the first time the cardioprotective effect of QUE through Nrf2 mechanisms, against the damage induced by a HC diet.

A wide range of evidence supports the cardioprotective effects of QUE relying mainly on its antioxidant properties [49, 50]. The antioxidant properties of QUE have been attributed to its ability to protect mitochondria and induce biogenesis by activating the Nrf2 signaling pathway [51]. Although the role of QUE in bioenergetics has been studied in cardioprotection in an ischemia-reperfusion model [52], this has not been addressed under a hypercholesterolemic/hyperglycemic model.

4.3. Quercetin Protects against the Alteration in Bioenergetics Induced by Cholesterol. Considering that ATP consumption per tissue weight in the heart is the highest in the body and that this organ has limited energy reserves, cardiac bioenergetics and mitochondrial function are a highly regulated and vital process [53, 54]. Adequate bioenergetics leading to maintaining ATP levels is essential to preserve the physiological function of the cell and tissues. In fact, we have reported that the HC diet promotes insulin release impairment, which causes hyperglycemia, by inducing bioenergetic deficiency in insulinoma cells [12]. In this

study, we found that this HC diet also induces a reduction in ATP levels in the heart, causing diastolic and morphological impairments, which were reversed by QUE treatment. From this viewpoint, a constant flux of ATP is essential to maintaining the cardiac contractile function [55]. Interestingly, it has been suggested that alterations in cardiac energy metabolism play a key role in the pathogenesis of diabetic cardiomyopathy [56]. Heart failure is associated with decreased mitochondrial biogenesis and function in both the heart and skeletal muscles, supporting the concept of a systemic mitochondrial cytopathy [57], which may be triggered by a HC diet.

Cardiac intermediary metabolism and its transcriptional networks are of interest to understanding the regulation of cardiac energetics, and PGC-1 α plays a central role in these pathways [55]. PGC-1 α is a key regulator of mitochondrial biogenesis, by inducing several genes involved in the tricarboxylic acid (TCA) cycle and antioxidant defense. In addition, PGC-1 α induces the mitochondrial transcription factor A (Tfam), an important factor for mitochondrial DNA (mtDNA) transcription, translation, and repair [58]. In this study, we found that a HC diet decreased PGC-1 α and increased UCP2 expression. PGC-1 α and mitochondrial function restoration have been associated with cardiac




FIGURE 6: Quercetin protects against the decrease in cardiac antioxidant defenses induced by high-cholesterol diet. Antioxidant defenses (a) GSH/GSSG ratio, (b) nuclear translocation of Nrf2, (c) HO-1 expression, and activities of (d) SOD, (e) catalase, and (f) glutathione peroxidase in the heart from rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin diet (CQ), high-cholesterol diet (HC), and high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.

function improvement [59]. We found that QUE prevented the HC diet-induced decrease in PGC-1 α and attenuated diastolic dysfunction. Lipid accumulation in the myocardium has detrimental effects on PGC-1 α expression and mitochondrial function, thus promoting contractile dysfunction [59]. In our study, a HC diet promoted cholesterol accumulation

in cardiac tissue that was associated with a reduction in mRNA PGC-1 α levels. The protein UCP2 is located in the mitochondrial inner membrane where it could act as a regulated protonophore, dissipating the mitochondrial membrane potential and thus decreasing the ATP production linked to oxygen consumption. In this regard, the HC diet




FIGURE 7: Quercetin protects against cardiac oxidative stress induced by high-cholesterol diet. (a) TBARS and (b) 8-isoprostane were measured in the heart from 12 h fasting rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin diet (CQ), high-cholesterol diet (HC), and high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, and **** $p < 0.0001$.




FIGURE 8: Quercetin protects against the decrease in ATP levels and the alterations of metabolic gene expression induced by high-cholesterol diet. (a) ATP levels, (b) *PGC-1 α* , and (c) *UCP2* expression in the hearts of rats fed for 4 weeks with control diet (C), control diet containing 0.5% quercetin diet (CQ), high-cholesterol diet (HC), and high-cholesterol diet containing 0.5% quercetin (HCQ). Values are expressed as mean \pm SEM. $N = 6-8$ rats/group. Two-way ANOVA test and Bonferroni posttest. Statistical differences: * $p < 0.05$ and *** $p < 0.001$.

may also impair intracellular bioenergetics by promoting *UCP2* expression, as was found in this study. *UCP2* (mRNA and protein expression) caused decreased cardiac mechanical

efficiency (hydraulic work/myocardial oxygen consumption) in a septic shock model in rats [60] and was associated with an impaired myocardial energy metabolism and decreased

ATP levels in a canine endotoxin shock model [61]. Increased UCP2 has been correlated with reduced cardiac efficiency in cardiac hypertrophy in hyperthyroidism [62]. It is noteworthy that mitochondrial uncoupling occurs in the hearts of diabetic db/db mice, mainly mediated by increased UCP activity, causing a deterioration of contractile function [63].

Although PPAR γ is not as highly expressed in cardiac tissue as PPAR α , it is still critical for cardiac function [64]. Remarkably, human hearts contain 8- to 15-fold higher PPAR γ mRNA levels than mouse hearts [65], suggesting that PPAR γ is more functional in humans, although its detrimental or beneficial effect on myocardial function is still controversial [66]. In the present study, the deleterious effect of a HC diet on cardiac function was accompanied by an increase on PPAR γ expression. It has been shown that overexpression of PPAR γ in mice created a dilated cardiomyopathy associated with increased lipid stores and altered mitochondrial architecture [65]. These effects were exacerbated under hyperglycemic conditions in a streptozotocin-induced diabetes model with increased cardiac PPAR γ expression in mice [65].

The protective effect of QUE against HC diet-induced diastolic dysfunction may lie in its ability to prevent cholesterol accumulation and an ATP reduction and to preserve PGC-1 α and UCP2 expression. It has been suggested that at least part of the cardioprotective effects of QUE resides in its ability to protect against mitochondrial damage in an ischemia/reperfusion model in rats [52]. Quercetin has been shown to prevent the increase of UCP2 expression in the liver from high-sucrose and HC diet-fed rabbits, which was associated with a decrease in lipid peroxidation and an increase in GSH content in this organ [67].

In conclusion, the molecular mechanisms that support the cardioprotective effects of QUE supplementation in rats exposed to a HC diet may be mediated by the upregulation of intracellular antioxidant mechanisms and improved bioenergetics of the heart. From this point of view, the mitochondria can be considered a pharmacological target to modulate structural and functional changes of the heart under impaired metabolic conditions. Exposure to high-cholesterol diets and the occurrence of oxidative stress and mitochondrial dysfunction are clearly important variables to consider in the follow-up of patients with increased cardiovascular risk.

Conflicts of Interest

Authors declare no conflict of interest.

Authors' Contributions

Catalina Carrasco-Pozo, Rodrigo L. Castillo, Emilio A. Herrera, Alejandro Gonzalez-Candia, and Marjorie Reyes-Farias performed the experiments. Juan Pedro Peña performed the echocardiographies. Catalina Carrasco-Pozo, Juan Pedro Peña, Rodrigo L. Castillo, Emilio A. Herrera, and Alejandro Gonzalez-Candia interpreted the results. Catalina Carrasco-Pozo, Emilio A. Herrera, and Rodrigo L.

Castillo drafted the manuscript. All authors commented and approved the submitted manuscript.

Acknowledgments

The present study was supported by FONDECYT Initiation into Research Grant no. 11130232 (Catalina Carrasco-Pozo) and FONDECYT Regular Grant no. 1151119 (Emilio A. Herrera).

Supplementary Materials

Supplementary Figure 1: ezetimibe protects against the increase on total cholesterol in plasma, cholesterol content in heart and heart weight induced by a high cholesterol diet. In rats fed for 4 weeks with control, diet (C), high cholesterol diet (HC) or high cholesterol diet containing 0.001% ezetimibe (HCE) the A) total cholesterol in plasma, B) cholesterol content in heart and C) the weight of the heart were measured after 12 h, fasting. Values are expressed as mean \pm SEM. $N=6-8$ rats/group. All one-way ANOVAs, Bonferroni post-test significances showed in each figure * $p < 0.05$, ** $p < 0.01$ and **** $p < 0.0001$. Supplementary Figure 2: ezetimibe protects against the alteration of the cardiac oxidative status induced by a high cholesterol diet. In heart from rats fed for 4 weeks with control diet (C), high cholesterol diet (HC) or high cholesterol diet containing 0.001% ezetimibe (HCE) the A) the GSH/GSSH and B) Lipid peroxidation were measured after 12 h fasting. Values are expressed as mean \pm SEM. $N=6-8$ rats/group. All one-way ANOVAs, Bonferroni post-test significances showed in each figure. *** $p < 0.001$ and **** $p < 0.0001$. Supplementary Figure 3: ezetimibe protects against the cardiac metabolic alterations induced by a high cholesterol diet. In heart from rats fed for 4 weeks with control diet (C), high cholesterol diet (HC) or cholesterol diet containing 0.001% ezetimibe (HCE) the A) ATP levels and the expression of B) PGC-1 α C) UCP2 and D) PPAR γ were measured after 12 h fasting. Values are expressed as mean \pm SEM. $N=6-8$ rats/group. All one-way ANOVAs, Bonferroni post-test significances showed in each figure. ** $p < 0.01$, *** $p < 0.001$ and **** $p < 0.0001$. Supplementary Table 1: list of primers used in this study for RT-PCR. ACTB, Beta-actin; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; PGC-1 α , Peroxisome proliferator-activated receptor gamma coactivator 1 alpha; PPAR γ , Peroxisome proliferator-activated receptor gamma; UCP2, mitochondrial uncoupling protein 2. (*Supplementary Materials*)

References

- [1] J. Cai, L. Yang, H. J. He et al., "Antioxidant capacity responsible for a hypocholesterolemia is independent of dietary cholesterol in adult rats fed rice protein," *Gene*, vol. 533, no. 1, pp. 57–66, 2014.
- [2] C. Csonka, M. Sarkozy, M. Pipicz, L. Dux, and T. Csont, "Modulation of hypercholesterolemia-induced oxidative/nitrative stress in the heart," *Oxidative Medicine and Cellular Longevity*, vol. 2016, Article ID 3863726, 23 pages, 2016.

- [3] Y. Chtourou, A. B. Slima, M. Makni, R. Gdoura, and H. Fetoui, "Naringenin protects cardiac hypercholesterolemia-induced oxidative stress and subsequent necroptosis in rats," *Pharmacological Reports*, vol. 67, no. 6, pp. 1090–1097, 2015.
- [4] V. Kamesh and T. Sumathi, "Antihypercholesterolemic effect of *Bacopa monniera* linn. on high cholesterol diet induced hypercholesterolemia in rats," *Asian Pacific Journal of Tropical Medicine*, vol. 5, no. 12, pp. 949–955, 2012.
- [5] N. Panth, K. R. Paudel, and K. Parajuli, "Reactive oxygen species: a key hallmark of cardiovascular disease," *Advances in Medicine*, vol. 2016, Article ID 9152732, 12 pages, 2016.
- [6] E. Osto, C. M. Matter, A. Kouroedov et al., "*c-Jun N-terminal kinase 2* deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress," *Circulation*, vol. 118, no. 20, pp. 2073–2080, 2008.
- [7] D. G. Harrison, "From ST segments to endothelial pathophysiology: hypercholesterolemia and endothelial superoxide production," *The Journal of Clinical Investigation*, vol. 124, no. 2, pp. 473–475, 2014.
- [8] E. Olea, M. T. Agapito, T. Gallego-Martin et al., "Intermittent hypoxia and diet-induced obesity: effects on oxidative status, sympathetic tone, plasma glucose and insulin levels, and arterial pressure," *Journal of Applied Physiology*, vol. 117, no. 7, pp. 706–719, 2014.
- [9] N. Goncalves, A. F. Silva, P. G. Rodrigues et al., "Early cardiac changes induced by a hypercaloric Western-type diet in "subclinical" obesity," *American Journal of Physiology Heart and Circulatory Physiology*, vol. 310, no. 6, pp. H655–H666, 2016.
- [10] B. Halliwell, "Dietary polyphenols: good, bad, or indifferent for your health?," *Cardiovascular Research*, vol. 73, no. 2, pp. 341–347, 2007.
- [11] F. Giampieri, J. M. Alvarez-Suarez, L. Mazzoni et al., "Polyphenol-rich strawberry extract protects human dermal fibroblasts against hydrogen peroxide oxidative damage and improves mitochondrial functionality," *Molecules*, vol. 19, no. 6, pp. 7798–7816, 2014.
- [12] C. Carrasco-Pozo, K. N. Tan, M. Reyes-Farias et al., "The deleterious effect of cholesterol and protection by quercetin on mitochondrial bioenergetics of pancreatic beta-cells, glycemic control and inflammation: *in vitro* and *in vivo* studies," *Redox Biology*, vol. 9, pp. 229–243, 2016.
- [13] G. D'Andrea, "Quercetin: a flavonol with multifaceted therapeutic applications?," *Fitoterapia*, vol. 106, pp. 256–271, 2015.
- [14] L. A. Ahmed, H. A. Salem, A. S. Attia, and M. E. El-Sayed, "Enhancement of amlodipine cardioprotection by quercetin in ischaemia/reperfusion injury in rats," *The Journal of Pharmacy and Pharmacology*, vol. 61, no. 9, pp. 1233–1241, 2009.
- [15] S. Arumugam, R. A. Thandavarayan, W. Arozal et al., "Quercetin offers cardioprotection against progression of experimental autoimmune myocarditis by suppression of oxidative and endoplasmic reticulum stress via endothelin-1/MAPK signalling," *Free Radical Research*, vol. 46, no. 2, pp. 154–163, 2012.
- [16] N. Katsiki, E. Theocharidou, A. Karagiannis, V. G. Athyros, and D. P. Mikhailidis, "Ezetimibe therapy for dyslipidemia: an update," *Current Pharmaceutical Design*, vol. 19, no. 17, pp. 3107–3114, 2013.
- [17] Y. S. Yoon, S. Uchida, O. Masuo et al., "Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor," *Circulation*, vol. 111, no. 16, pp. 2073–2085, 2005.
- [18] S. Gao, D. Ho, D. E. Vatner, and S. F. Vatner, "Echocardiography in mice," *Current Protocols in Mouse Biology*, vol. 1, pp. 71–83, 2011.
- [19] P. J. Hissin and R. Hilf, "A fluorometric method for determination of oxidized and reduced glutathione in tissues," *Analytical Biochemistry*, vol. 74, no. 1, pp. 214–226, 1976.
- [20] H. Ohkawa, N. Ohishi, and K. Yagi, "Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction," *Analytical Biochemistry*, vol. 95, no. 2, pp. 351–358, 1979.
- [21] C. Nebot, M. Moutet, P. Huet, J. Z. Xu, J. C. Yadan, and J. Chaudiere, "Spectrophotometric assay of superoxide dismutase activity based on the activated autoxidation of a tetracyclic catechol," *Analytical Biochemistry*, vol. 214, no. 2, pp. 442–451, 1993.
- [22] H. Aebi, "Catalase A2 - Bergmeyer," in *Methods of Enzymatic Analysis*, H. Ulrich, Ed., pp. 673–684, Academic Press, 2nd edition, 1974.
- [23] L. Flohe and W. A. Gunzler, "Assays of glutathione peroxidase," *Methods in Enzymology*, vol. 105, pp. 114–121, 1984.
- [24] C. Carrasco-Pozo, R. L. Castillo, C. Beltrán, A. Miranda, J. Fuentes, and M. Gotteland, "Molecular mechanisms of gastrointestinal protection by quercetin against indomethacin-induced damage: role of NF- κ B and Nrf2," *The Journal of Nutritional Biochemistry*, vol. 27, pp. 289–298, 2016.
- [25] M. G. Hadera, O. B. Smeland, T. S. McDonald, K. N. Tan, U. Sonnewald, and K. Borges, "Triheptanoin partially restores levels of tricarboxylic acid cycle intermediates in the mouse pilocarpine model of epilepsy," *Journal of Neurochemistry*, vol. 129, no. 1, pp. 107–119, 2014.
- [26] H. Bugger and C. Bode, "The vulnerable myocardium. Diabetic cardiomyopathy," *Hämostaseologie*, vol. 35, no. 1, pp. 17–24, 2015.
- [27] E. Ulasova, J. Perez, B. G. Hill et al., "Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse," *Redox Biology*, vol. 1, no. 1, pp. 381–386, 2013.
- [28] Y. Shen, N. C. Ward, J. M. Hodgson et al., "Dietary quercetin attenuates oxidant-induced endothelial dysfunction and atherosclerosis in apolipoprotein E knockout mice fed a high-fat diet: a critical role for heme oxygenase-1," *Free Radical Biology and Medicine*, vol. 65, pp. 908–915, 2013.
- [29] W. M. Loke, J. M. Proudfoot, J. M. Hodgson et al., "Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein E-knockout mice by alleviating inflammation and endothelial dysfunction," *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 30, no. 4, pp. 749–757, 2010.
- [30] R. W. Hubbard, Y. Ono, and A. Sanchez, "Atherogenic effect of oxidized products of cholesterol," *Progress in Food & Nutrition Science*, vol. 13, no. 1, pp. 17–44, 1989.
- [31] T. Celik, U. C. Yuksel, F. Fici et al., "Vascular inflammation and aortic stiffness relate to early left ventricular diastolic dysfunction in prehypertension," *Blood Pressure*, vol. 22, no. 2, pp. 94–100, 2013.
- [32] N. Merlet, D. Busseuil, T. Mihalache-Avram et al., "HDL mimetic peptide CER-522 treatment regresses left ventricular diastolic dysfunction in cholesterol-fed rabbits," *International Journal of Cardiology*, vol. 215, pp. 364–371, 2016.

- [33] A. Frustaci, J. Kajstura, C. Chimenti et al., "Myocardial cell death in human diabetes," *Circulation Research*, vol. 87, no. 12, pp. 1123–1132, 2000.
- [34] C. Carrasco-Pozo, M. Gotteland, R. L. Castillo, and C. Chen, "3,4-Dihydroxyphenylacetic acid, a microbiota-derived metabolite of quercetin, protects against pancreatic β -cells dysfunction induced by high cholesterol," *Experimental Cell Research*, vol. 334, no. 2, pp. 270–282, 2015.
- [35] S. Boudina and E. D. Abel, "Diabetic cardiomyopathy revisited," *Circulation*, vol. 115, no. 25, pp. 3213–3223, 2007.
- [36] T. Munzel, T. Gori, J. F. Keane Jr., C. Maack, and A. Daiber, "Pathophysiological role of oxidative stress in systolic and diastolic heart failure and its therapeutic implications," *European Heart Journal*, vol. 36, no. 38, pp. 2555–2564, 2015.
- [37] A. C. Kohler, C. M. Sag, and L. S. Maier, "Reactive oxygen species and excitation-contraction coupling in the context of cardiac pathology," *Journal of Molecular and Cellular Cardiology*, vol. 73, pp. 92–102, 2014.
- [38] N. Kaludercic, E. Takimoto, T. Nagayama et al., "Monoamine oxidase A-mediated enhanced catabolism of norepinephrine contributes to adverse remodeling and pump failure in hearts with pressure overload," *Circulation Research*, vol. 106, no. 1, pp. 193–202, 2010.
- [39] G. Koncsos, Z. V. Varga, T. Baranyai et al., "Diastolic dysfunction in prediabetic male rats: role of mitochondrial oxidative stress," *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 311, no. 4, pp. H927–H943, 2016.
- [40] J. Chung, E. M. Jeong, Y. Go et al., "Mitochondria-targeted antioxidant ameliorates diet-induced diabetes and diastolic dysfunction," *Journal of the American College of Cardiology*, vol. 61, no. 10, p. E597, 2013.
- [41] M. Luo, X. Guan, E. D. Luczak et al., "Diabetes increases mortality after myocardial infarction by oxidizing CaMKII," *The Journal of Clinical Investigation*, vol. 123, no. 3, pp. 1262–1274, 2013.
- [42] M. Fiorani, A. Guidarelli, M. Blasa et al., "Mitochondria accumulate large amounts of quercetin: prevention of mitochondrial damage and release upon oxidation of the extramitochondrial fraction of the flavonoid," *The Journal of Nutritional Biochemistry*, vol. 21, no. 5, pp. 397–404, 2010.
- [43] C. Carrasco-Pozo, E. Pastene, C. Vergara, M. Zapata, C. Sandoval, and M. Gotteland, "Stimulation of cytosolic and mitochondrial calcium mobilization by indomethacin in Caco-2 cells: modulation by the polyphenols quercetin, resveratrol and rutin," *Biochimica et Biophysica Acta (BBA) - Biomembranes*, vol. 12, no. 61, p. 26, 2012.
- [44] J. Li, T. Ichikawa, J. S. Janicki, and T. Cui, "Targeting the Nrf2 pathway against cardiovascular disease," *Expert Opinion on Therapeutic Targets*, vol. 13, no. 7, pp. 785–794, 2009.
- [45] A. Loboda, M. Damulewicz, E. Pyza, A. Jozkowicz, and J. Dulak, "Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism," *Cellular and Molecular Life Sciences*, vol. 73, no. 17, pp. 3221–3247, 2016.
- [46] L. E. Otterbein, R. Foresti, and R. Motterlini, "Heme oxygenase-1 and carbon monoxide in the heart: the balancing act between danger signaling and pro-survival," *Circulation Research*, vol. 118, no. 12, pp. 1940–1959, 2016.
- [47] C. Li, W.-J. Zhang, and B. Frei, "Quercetin inhibits LPS-induced adhesion molecule expression and oxidant production in human aortic endothelial cells by p38-mediated Nrf2 activation and antioxidant enzyme induction," *Redox Biology*, vol. 9, pp. 104–113, 2016.
- [48] S. K. Panchal, H. Poudyal, and L. Brown, "Quercetin ameliorates cardiovascular, hepatic, and metabolic changes in diet-induced metabolic syndrome in rats," *The Journal of Nutrition*, vol. 142, no. 6, pp. 1026–1032, 2012.
- [49] M. Kumar, E. R. Kasala, L. N. Bodduluru, V. Kumar, and M. Lahkar, "Molecular and biochemical evidence on the protective effects of quercetin in isoproterenol-induced acute myocardial injury in rats," *Journal of Biochemical and Molecular Toxicology*, vol. 31, no. 1, pp. 1–8, 2017.
- [50] N. Ozbek, E. B. Bali, and C. Karasu, "Quercetin and hydroxytyrosol attenuates xanthine/xanthine oxidase-induced toxicity in H9c2 cardiomyocytes by regulation of oxidative stress and stress-sensitive signaling pathways," *General Physiology and Biophysics*, vol. 34, no. 4, pp. 407–414, 2015.
- [51] X. Li, H. Wang, Y. Gao et al., "Protective effects of quercetin on mitochondrial biogenesis in experimental traumatic brain injury via the Nrf2 signaling pathway," *PLoS One*, vol. 11, no. 10, 2016.
- [52] P. S. Brookes, S. B. Digerness, D. A. Parks, and V. Darley-Usmar, "Mitochondrial function in response to cardiac ischemia-reperfusion after oral treatment with quercetin," *Free Radical Biology & Medicine*, vol. 32, no. 11, pp. 1220–1228, 2002.
- [53] D. M. Krzywanski, D. R. Moellering, J. L. Fetterman, K. J. Dunham-Snary, M. J. Sammy, and S. W. Ballinger, "The mitochondrial paradigm for cardiovascular disease susceptibility and cellular function: a complementary concept to Mendelian genetics," *Laboratory Investigation*, vol. 91, no. 8, pp. 1122–1135, 2011.
- [54] A. Ramachandran, A. L. Levonen, P. S. Brookes et al., "Mitochondria, nitric oxide, and cardiovascular dysfunction," *Free Radical Biology & Medicine*, vol. 33, no. 11, pp. 1465–1474, 2002.
- [55] G. C. Rowe, A. Jiang, and Z. Arany, "PGC-1 coactivators in cardiac development and disease," *Circulation Research*, vol. 107, no. 7, pp. 825–838, 2010.
- [56] H. Bugger and E. D. Abel, "Mitochondria in the diabetic heart," *Cardiovascular Research*, vol. 88, no. 2, pp. 229–240, 2010.
- [57] M. G. Rosca and C. L. Hoppel, "Mitochondrial dysfunction in heart failure," *Heart Failure Reviews*, vol. 18, no. 5, pp. 607–622, 2013.
- [58] R. Ventura-Clapier, A. Garnier, and V. Veksler, "Transcriptional control of mitochondrial biogenesis: the central role of PGC-1 α ," *Cardiovascular Research*, vol. 79, no. 2, pp. 208–217, 2008.
- [59] J. G. Duncan, "Peroxisome proliferator activated receptor-alpha (PPAR α) and PPAR gamma coactivator-1alpha (PGC-1 α) regulation of cardiac metabolism in diabetes," *Pediatric Cardiology*, vol. 32, no. 3, pp. 323–328, 2011.
- [60] M. J. Roshon, J. A. Kline, L. R. Thornton, and J. A. Watts, "Cardiac UCP2 expression and myocardial oxidative metabolism during acute septic shock in the rat," *Shock*, vol. 19, no. 6, pp. 570–6, 2003.
- [61] X. Wang, D. Liu, W. Chai, Y. Long, L. Su, and R. Yang, "The role of uncoupling protein 2 during myocardial dysfunction in a canine model of endotoxin shock," *Shock*, vol. 43, no. 3, pp. 292–297, 2015.

- [62] E. A. Boehm, B. E. Jones, G. K. Radda, R. L. Veech, and K. Clarke, "Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart," *American Journal of Physiology. Heart and Circulatory Physiology*, vol. 280, no. 3, pp. H977–H983, 2001.
- [63] S. Boudina, S. Sena, H. Theobald et al., "Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins," *Diabetes*, vol. 56, no. 10, pp. 2457–2466, 2007.
- [64] S. Z. Duan, C. Y. Ivashchenko, M. W. Russell, D. S. Milstone, and R. M. Mortensen, "Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor- γ both induce cardiac hypertrophy in mice," *Circulation Research*, vol. 97, no. 4, pp. 372–379, 2005.
- [65] N. H. Son, T. S. Park, H. Yamashita et al., "Cardiomyocyte expression of PPAR γ leads to cardiac dysfunction in mice," *The Journal of Clinical Investigation*, vol. 117, no. 10, pp. 2791–2801, 2007.
- [66] C. J. Pol, M. Lieu, and K. Drosatos, "PPARs: protectors or opponents of myocardial function?," *PPAR Research*, vol. 2015, Article ID 835985, 19 pages, 2015.
- [67] M. Kobori, S. Masumoto, Y. Akimoto, and H. Oike, "Chronic dietary intake of quercetin alleviates hepatic fat accumulation associated with consumption of a Western-style diet in C57/BL6J mice," *Molecular Nutrition & Food Research*, vol. 55, no. 4, pp. 530–540, 2011.



Hindawi

Submit your manuscripts at
www.hindawi.com

